- Ariad Pharmaceuticals (ARIA -3.6%) began the day in the red and has traded steadily lower throughout the session.
- Perhaps weighing on the shares is the news that Clovis Oncology (CLVS -11.1%) has received no interest from buyers after hiring Credit Suisse to explore strategic options.
- Like CLVS' lead compound CO-1686, ARIA's AP26113 is an EGFR inhibitor.
- When news hit last week that CLVS was pursuing a sale, ARIA spiked.
From other sites
at Nasdaq.com (Wed, 11:31AM)
at Nasdaq.com (Feb 26, 2015)
at Benzinga.com (Feb 20, 2015)
at Nasdaq.com (Jan 23, 2015)
at CNBC.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs